Photo courtesy of Dean Forbes, © 2006
We have completed our addition of a new Clinical Studies
section to the website! This section now contains information on clinical trials at FHCRC currently open and enrolling for treatment of leukemia or lymphoma in patients with HIV – the previously announced protocol 1410, as well as protocols 2212 and 2485.
Currently, defeatHIV clinical studies are focused on treating HIV infected individuals who also suffer from hematologic malignancies such as leukemia or lymphoma. While today’s HIV therapy can often suppress the virus and minimize its effects on the body, the combination of HIV and cancer diagnoses has historically been difficult for clinicians to manage. The powerful drugs often required to treat blood cancers can exacerbate the HIV infection, ultimately making things worse for the patient. However, recent advances in hematopoietic cell transplantation (HCT) have demonstrated remarkable results in people suffering from HIV and cancers of the blood (see Berlin Patient). Our goal is to build on these successes and utilize our expertise in HIV virology, transplantation biology and genome editing technologies to develop a new therapeutic approach for eradicating HIV.
We hope this information will serve as a resource for patients, clinicians and other individuals interested in our clinical research efforts. Follow the link to our Clinical Studies page and learn more about these studies, eligibility criteria and clinic contact information.
Seattle Cancer Care Alliance (SCCA)
First defeatHIV Clinical Study Is Enrolling!
We are excited to announce recruitment for the first defeatHIV clinical study is open! This is an important step in our HIV eradication efforts and as such, we will be updating defeatHIV.org to include further information on our clinical studies for HIV patients. Read on for study details, eligibility criteria and clinic contact information.
Protocol 1410: Treatment with Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with Human Immunodeficiency Virus-1 Using a Non-Ablative Conditioning Regimen Containing Total Body Irradiation in Combination with Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil
Purpose: The purpose of the treatment on this study is to replace bone marrow cells with healthy cells donated by a person with a healthy immune system. The new bone marrow or hematopoietic stem cells have the ability to grow into new blood and immune systems. We believe that HAART may give us a new way to help control the HIV and prevent it from infecting the new bone marrow cells. We will monitor the level of HIV in the latent reservoir to determine whether HAART drugs can continue to control or even reduce HIV after hematopoietic stem cell transplantation (HSCT).
Major eligibility criteria:
- Patients with a hematologic malignancy in remission treatable with HSCT, who:
a. have been on HAART for at least one month, and
b. have a HIV load <5000 copies/ml.
- Or, Patients without malignancy who meet these criteria:
a. have been treated with more than one HAART regimen for at least six continuous months, and
b. have a HIV load <50 copies/ml, and
c. have a CD4 count <100 cells/ml.
- Patients must have an HLA-matched donor.
- Patients must be <65 years old.
Contact: For more information, contact the Clinical Coordinator Office at the Seattle Cancer Care Alliance (1-800-804-8824) and reference protocol number 1410.
defeatHIV clinical studies are performed in Seattle, WA at the Seattle Cancer Care Alliance (SCCA). The SCCA is the treatment arm of the world-renowned Fred Hutchinson Cancer Research Center, and operates the largest bone marrow transplant program in the world.